The six fictional programs used throughout the book, one printable card each (US Letter, one to two pages). Each card reproduces the case from Appendix D (history, trials, reference safety information, the safety events that shape its DSURs, what it tests) and lists the chapters, sections, figures and exercises that use it.
| Item | Format | What it is for | Book reference |
|---|---|---|---|
| case-A-ONK-417.docx | Word | Case A: ONK-417, oral kinase inhibitor, solid tumors. First-in-human program across DSURs 1 to 3: the first DSUR with little data, actions taken, and an evolving Summary of Important Risks | Appendix D, Case A; Chapters 1, 2, 6–9, 11–13, 16; Figures 9.3, 11.1 |
| case-B-XB-7.docx | Word | Case B: XB-7, monoclonal antibody, autoimmune disease. Blinded Phase 3 program, DSUR 5: exposure without unblinding, a mid-period IB change adding sepsis, Section 18, late-breaking information, QC and executive review | Appendix D, Case B; Chapters 1–6, 8–13, 15, 17; basis of worked-example/ |
| case-C-CX-3.docx | Word | Case C: CX-3, marketed oral anticoagulant, new indication. DSUR and PBRER side by side and synchronization, marketing experience, regional overlays, a regulator question | Appendix D, Case C; Chapters 1, 2, 4, 5, 7, 8, 11, 14–16; Figures 14.2, 15.3, 16.2 |
| case-D-VD-12.docx | Word | Case D: VD-12, adjuvanted vaccine, healthy adults. Low event rates against background incidence, adverse events of special interest, endpoint exclusions | Appendix D, Case D; Chapters 1, 5, 6, 9 (Exercise 1), 10, 12, 13; Figures 5.3, 10.4 |
| case-E-GT-5.docx | Word | Case E: GT-5, AAV gene therapy, rare neuromuscular disease. Tiny denominators, delayed and theoretical risks, long-term follow-up, the final-DSUR statement | Appendix D, Case E; Chapters 1, 5, 9, 11, 12 (Exercise 1), 13, 16 |
| case-F-PX-22.docx | Word | Case F: PX-22, small molecule, co-developed. Separate DSURs with a partner, data gaps, divergent RSI, Section 14 | Appendix D, Case F; Chapters 1, 2, 4, 5, 7, 12, 17 |
Fictional data only; not regulatory advice. Licensed under CC BY-NC 4.0; commercial use needs a corporate license.